At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a
meaningful difference on the lives of patients. Today, Pfizer Oncology has an industry-leading
portfolio of 14 approved cancer medicines across 22 indications, including breast, prostate, kidney,
lung and hematology. We also have two oncology biosimilar medicines approved globally and
several assets in mid to late-stage development for the treatment of cancer or as supportive care.
Pfizer Oncology is striving to change the trajectory of cancer.